Candriam Luxembourg S.C.A. boosted its stake in shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 84.4% during the second quarter, Holdings Channel reports. The firm owned 59,000 shares of the biotechnology company’s stock after buying an additional 27,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Five Prime Therapeutics were worth $1,777,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Teachers Advisors LLC increased its position in shares of Five Prime Therapeutics by 0.7% in the fourth quarter. Teachers Advisors LLC now owns 238,428 shares of the biotechnology company’s stock valued at $11,948,000 after buying an additional 1,558 shares during the period. Creative Planning increased its position in shares of Five Prime Therapeutics by 42.6% in the first quarter. Creative Planning now owns 6,690 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 2,000 shares during the period. Adams Diversified Equity Fund Inc. increased its position in shares of Five Prime Therapeutics by 56.3% in the first quarter. Adams Diversified Equity Fund Inc. now owns 18,600 shares of the biotechnology company’s stock valued at $672,000 after buying an additional 6,700 shares during the period. Rockefeller Financial Services Inc. purchased a new position in shares of Five Prime Therapeutics during the second quarter valued at $210,000. Finally, Alliancebernstein L.P. increased its position in shares of Five Prime Therapeutics by 9.2% in the first quarter. Alliancebernstein L.P. now owns 97,770 shares of the biotechnology company’s stock valued at $3,534,000 after buying an additional 8,220 shares during the period. Institutional investors and hedge funds own 85.10% of the company’s stock.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) opened at 27.83 on Friday. The company’s market capitalization is $777.71 million. The firm’s 50-day moving average is $29.46 and its 200-day moving average is $34.75. Five Prime Therapeutics, Inc. has a 1-year low of $25.97 and a 1-year high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.15) by $0.43. Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The firm had revenue of $7.80 million during the quarter, compared to the consensus estimate of $8.32 million. During the same period in the prior year, the business earned ($0.49) EPS. The company’s revenue for the quarter was down 16.1% compared to the same quarter last year. Equities research analysts predict that Five Prime Therapeutics, Inc. will post ($5.10) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Candriam Luxembourg S.C.A. Has $1.78 Million Position in Five Prime Therapeutics, Inc. (NASDAQ:FPRX)” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-has-1-78-million-position-in-five-prime-therapeutics-inc-nasdaqfprx/1476934.html.

Several research analysts have recently weighed in on FPRX shares. ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Jefferies Group LLC restated a “buy” rating and issued a $55.00 target price on shares of Five Prime Therapeutics in a research note on Friday, May 5th. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research note on Wednesday, April 26th. Finally, BidaskClub downgraded shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $60.80.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.